{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=5", "query": { "condition": "Advanced Malignancy", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 9803, "total_pages": 981, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T16:59:24.544Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06257758", "title": "A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Breast Cancer", "Recurrent Ovarian Cancer", "Prostate Cancer" ], "interventions": [ { "name": "VIO-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valerio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2024-01-10", "completion_date": "2025-01-01", "has_results": false, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 3, "location_summary": "Lake Mary, Florida • Oklahoma City, Oklahoma • San Antonio, Texas", "locations": [ { "city": "Lake Mary", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06257758" }, { "nct_id": "NCT04928508", "title": "Advanced or Recurrent Solid Tumors Treated With SHetA2", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "OK-1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2022-07-27", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04928508" }, { "nct_id": "NCT04805333", "title": "Phase 1 Dose Escalation of ArtemiCoffee", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Artemisia annua 450mg", "type": "DRUG" }, { "name": "Artemisia annua 900mg", "type": "DRUG" }, { "name": "Artemisia annua 1350mg", "type": "DRUG" }, { "name": "Artemisia annua 1800mg", "type": "DRUG" }, { "name": "Artemisia annua - recommended phase II dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Frederick R. Ueland, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2021-03-26", "completion_date": "2025-02-04", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04805333" }, { "nct_id": "NCT03359733", "title": "A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Malignant", "Advanced Solid Neoplasms" ], "interventions": [ { "name": "TAK-659", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-02-28", "completion_date": "2019-08-20", "has_results": false, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Detroit, Michigan • The Bronx, New York", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03359733" }, { "nct_id": "NCT00704158", "title": "Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "CR011-vcMMAE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CuraGen Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2008-06", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2015-02-19", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 5, "location_summary": "Fort Myers, Florida • Lake Worth, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00704158" }, { "nct_id": "NCT00728949", "title": "A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "IMC-A12 (cixutumumab)", "type": "BIOLOGICAL" }, { "name": "tamoxifen", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 93, "start_date": "2008-08", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00728949" }, { "nct_id": "NCT04685135", "title": "Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non Small Cell Lung Cancer", "Advanced Non Small Cell Lung Cancer" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 453, "start_date": "2021-02-23", "completion_date": "2026-10-30", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 112, "location_summary": "Cerritos, California • Duarte, California • Glendale, California + 82 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04685135" }, { "nct_id": "NCT02178436", "title": "Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mohammed Najeeb Al Hallak", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 15, "start_date": "2014-10-31", "completion_date": "2023-04-05", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 2, "location_summary": "Detroit, Michigan • Stony Brook, New York", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02178436" }, { "nct_id": "NCT02228811", "title": "A Study of DCC-2701 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Tumors", "Metastatic Solid Tumors", "Cancers With MET Genomic Alterations", "Cancers With TRK Genomic Alterations" ], "interventions": [ { "name": "DCC-2701 tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2014-06", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2018-02-01", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 5, "location_summary": "Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228811" }, { "nct_id": "NCT05098132", "title": "Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Untreated Advanced NSCLC", "1st Line NSCLC" ], "interventions": [ { "name": "STK-012", "type": "DRUG" }, { "name": "pembrolizumab KEYTRUDA®", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synthekine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2022-01-25", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-28T16:59:24.544Z", "location_count": 33, "location_summary": "Tucson, Arizona • Beverly Hills, California • Fullerton, California + 26 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098132" } ] }